Cipla
Adil Zainulbhai is an accomplished leader with extensive experience in governance and advisory roles across various prestigious organizations. Currently serving as Chairman of the Board of Governors at the Indian Institute of Technology, Ropar, and as a Board Member of the Open Network For Digital Commerce, Zainulbhai also leads the Capacity Building Commission as Chairman. Their involvement with the Piramal Foundation and Network 18 as a Board Member, along with positions as Non-Executive Director at Cipla Ltd. and Senior Advisor at McKinsey & Company, highlights a robust commitment to strategic development and corporate governance. Zainulbhai has held significant independent director roles at Larsen & Toubro and Reliance, along with a notable tenure as Chairman of the Quality Council of India. Educational credentials include an MBA from Harvard Business School and a Bachelor of Technology in Mechanical Engineering from the Indian Institute of Technology, Bombay.
This person is not in the org chart
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.